Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 0 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 0 |
Forrest at al. (procyclic) | no | yes: 0 |
Silverman et al. | no | yes: 0 |
Pissara et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 6 |
NetGPI | no | yes: 0, no: 6 |
Term | Name | Level | Count |
---|---|---|---|
GO:0016020 | membrane | 2 | 6 |
GO:0110165 | cellular anatomical entity | 1 | 6 |
Related structures:
AlphaFold database: E9ARA2
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_MEL_PAP_1 | 53 | 59 | PF00089 | 0.471 |
CLV_NRD_NRD_1 | 185 | 187 | PF00675 | 0.674 |
CLV_NRD_NRD_1 | 64 | 66 | PF00675 | 0.532 |
CLV_PCSK_SKI1_1 | 135 | 139 | PF00082 | 0.594 |
CLV_Separin_Metazoa | 5 | 9 | PF03568 | 0.657 |
DEG_APCC_DBOX_1 | 78 | 86 | PF00400 | 0.595 |
DEG_ODPH_VHL_1 | 53 | 64 | PF01847 | 0.704 |
DOC_CKS1_1 | 113 | 118 | PF01111 | 0.474 |
DOC_CKS1_1 | 43 | 48 | PF01111 | 0.674 |
DOC_PP1_RVXF_1 | 133 | 139 | PF00149 | 0.463 |
DOC_PP1_RVXF_1 | 31 | 37 | PF00149 | 0.703 |
DOC_PP1_RVXF_1 | 64 | 71 | PF00149 | 0.639 |
DOC_USP7_MATH_1 | 129 | 133 | PF00917 | 0.572 |
DOC_USP7_MATH_1 | 159 | 163 | PF00917 | 0.547 |
DOC_USP7_UBL2_3 | 72 | 76 | PF12436 | 0.649 |
DOC_WW_Pin1_4 | 112 | 117 | PF00397 | 0.450 |
DOC_WW_Pin1_4 | 42 | 47 | PF00397 | 0.676 |
LIG_14-3-3_CanoR_1 | 107 | 111 | PF00244 | 0.407 |
LIG_14-3-3_CanoR_1 | 65 | 71 | PF00244 | 0.719 |
LIG_14-3-3_CanoR_1 | 79 | 83 | PF00244 | 0.324 |
LIG_BIR_III_4 | 24 | 28 | PF00653 | 0.657 |
LIG_FHA_1 | 131 | 137 | PF00498 | 0.478 |
LIG_FHA_1 | 17 | 23 | PF00498 | 0.677 |
LIG_FHA_1 | 36 | 42 | PF00498 | 0.637 |
LIG_FHA_2 | 11 | 17 | PF00498 | 0.678 |
LIG_LIR_Apic_2 | 40 | 46 | PF02991 | 0.675 |
LIG_LIR_Gen_1 | 13 | 22 | PF02991 | 0.723 |
LIG_LIR_Gen_1 | 81 | 92 | PF02991 | 0.423 |
LIG_LIR_Nem_3 | 13 | 17 | PF02991 | 0.696 |
LIG_LIR_Nem_3 | 69 | 73 | PF02991 | 0.611 |
LIG_LIR_Nem_3 | 81 | 87 | PF02991 | 0.368 |
LIG_LYPXL_yS_3 | 77 | 80 | PF13949 | 0.700 |
LIG_NRP_CendR_1 | 186 | 188 | PF00754 | 0.690 |
LIG_Pex14_1 | 97 | 101 | PF04695 | 0.368 |
LIG_SH2_CRK | 43 | 47 | PF00017 | 0.706 |
LIG_SH2_CRK | 59 | 63 | PF00017 | 0.660 |
LIG_SH2_GRB2like | 84 | 87 | PF00017 | 0.423 |
LIG_SH2_NCK_1 | 59 | 63 | PF00017 | 0.699 |
LIG_SH2_PTP2 | 84 | 87 | PF00017 | 0.487 |
LIG_SH2_SRC | 14 | 17 | PF00017 | 0.720 |
LIG_SH2_SRC | 84 | 87 | PF00017 | 0.423 |
LIG_SH2_STAT5 | 163 | 166 | PF00017 | 0.467 |
LIG_SH2_STAT5 | 29 | 32 | PF00017 | 0.663 |
LIG_SH2_STAT5 | 84 | 87 | PF00017 | 0.423 |
LIG_SH3_3 | 31 | 37 | PF00018 | 0.685 |
LIG_TYR_ITIM | 82 | 87 | PF00017 | 0.487 |
MOD_GlcNHglycan | 179 | 183 | PF01048 | 0.745 |
MOD_GSK3_1 | 159 | 166 | PF00069 | 0.477 |
MOD_N-GLC_1 | 130 | 135 | PF02516 | 0.770 |
MOD_N-GLC_2 | 153 | 155 | PF02516 | 0.542 |
MOD_PIKK_1 | 130 | 136 | PF00454 | 0.481 |
MOD_PKA_2 | 106 | 112 | PF00069 | 0.449 |
MOD_PKA_2 | 78 | 84 | PF00069 | 0.491 |
MOD_Plk_1 | 159 | 165 | PF00069 | 0.524 |
MOD_Plk_4 | 159 | 165 | PF00069 | 0.548 |
MOD_Plk_4 | 66 | 72 | PF00069 | 0.608 |
MOD_ProDKin_1 | 112 | 118 | PF00069 | 0.453 |
MOD_ProDKin_1 | 42 | 48 | PF00069 | 0.673 |
MOD_SUMO_for_1 | 25 | 28 | PF00179 | 0.710 |
TRG_DiLeu_BaEn_1 | 142 | 147 | PF01217 | 0.456 |
TRG_ENDOCYTIC_2 | 14 | 17 | PF00928 | 0.675 |
TRG_ENDOCYTIC_2 | 59 | 62 | PF00928 | 0.635 |
TRG_ENDOCYTIC_2 | 77 | 80 | PF00928 | 0.590 |
TRG_ENDOCYTIC_2 | 84 | 87 | PF00928 | 0.368 |
TRG_ER_diArg_1 | 185 | 188 | PF00400 | 0.480 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A0A0S4J6W1 | Bodo saltans | 61% | 72% |
A0A3S5H718 | Leishmania donovani | 96% | 100% |
A0A422NAT4 | Trypanosoma rangeli | 67% | 67% |
A4HXK7 | Leishmania infantum | 96% | 100% |
Q4QE61 | Leishmania major | 96% | 100% |